Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

被引：36

作者：

Friedman, Claire F. ^{[1
]}

Postow, Michael A. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 04期

关键词：

Immunotherapy; Checkpoint blockade; Ipilimumab; Nivolumab; Pembrolizumab; Biomarkers; PD-1; PD-L1; CTLA-4; Neoantigens; Melanoma; METASTATIC MELANOMA PATIENTS; T-CELL RESPONSES; CTLA-4; BLOCKADE; CLINICAL-RESPONSE; PD-1; IPILIMUMAB TREATMENT; NY-ESO-1; ANTIBODY; SUPPRESSOR-CELLS; NIVOLUMAB; SAFETY;

D O I：

10.1007/s11912-016-0509-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The immune system plays an essential role in the surveillance and eradication of neoplastic cells. This interaction is modulated via immunologic regulators (checkpoints). Antibodies that block the checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the programmed cell death protein 1 pathway (PD1/PD-L1) have demonstrated efficacy in a number of malignancies. However, response rates are variable, and administration of these antibodies can be associated with immune-related adverse events. Therefore, researchers are engaged in an effort to discover biomarkers that may predict response to these agents. This review focuses on potential blood and tumor-based biomarkers that have been assessed in patients treated with these checkpoint-blocking antibodies.

引用

页码：1 / 7

页数：7

共 65 条

[1]

Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2]

[Anonymous], N ENGL J MED

[3]

[Anonymous], 2014, J CLIN ONCOL S, DOI DOI 10.1200/JCO.2013.54.6911

[4]

[Anonymous], 2013, J IMMUNOTHER CANCER

[5]

[Anonymous], 2014, J TRANSL MED

[6]

[Anonymous], J CLIN ONCOL

[7]

Antonia SJ, 2013, J THORAC ONCOL, V8, pS1

[8]

Callahan MK, 2013, J CLIN ONCOL, V31

[9]

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial [J].

Carthon, Bradley C. ;

Wolchok, Jedd D. ;

Yuan, Jianda ;

Kamat, Ashish ;

Tang, Derek S. Ng ;

Sun, Jingjing ;

Ku, Geoffrey ;

Troncoso, Patricia ;

Logothetis, Christopher J. ;

Allison, James P. ;

Sharma, Padmanee .

CLINICAL CANCER RESEARCH, 2010, 16 (10) :2861-2871

[10]

Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients [J].

Cha, Edward ;

Klinger, Mark ;

Hou, Yafei ;

Cummings, Craig ;

Ribas, Antoni ;

Faham, Malek ;

Fong, Lawrence .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (238)

← 1 2 3 4 5 6 7 →